Results From Neurotech’s NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect On Photoreceptors

Neurotech Pharmaceuticals, Inc. announced that the Company’s product candidate, NT-501, demonstrated a strong biologic effect in two Phase 2 clinical trials for retinitis pigmentosa (RP). RP is a slowly developing condition that causes the progressive degeneration of rod & cone photoreceptor cells in the retina that over time diminishes night and peripheral vision and eventually leads to blindness. RP is an orphan-designated indication for which there are currently no approved treatments.

More: continued here

Filed under: Eye Health on June 1st, 2009